51![Microsoft Word - CRW Final Report- Screening for Pompe Disease 06042013_FinalEdits_CLEAN.docx Microsoft Word - CRW Final Report- Screening for Pompe Disease 06042013_FinalEdits_CLEAN.docx](https://www.pdfsearch.io/img/79bb19d05bd1b36041f6e3ecfce9f9ec.jpg) | Add to Reading ListSource URL: www.hrsa.govLanguage: English - Date: 2013-06-20 16:06:33
|
---|
52![EVIDENCE REVIEW: POMPE DISEASE EVIDENCE REVIEW: POMPE DISEASE](https://www.pdfsearch.io/img/44d38ab7e167a52d90915fedfc36f902.jpg) | Add to Reading ListSource URL: www.hrsa.govLanguage: English - Date: 2012-01-07 00:54:21
|
---|
53![February 26, 2013 Press Release Mitsubishi Tanabe Pharma Corporation TENELIA® 20mg tablets, a Treatment for Type 2 Diabetes Mellitus Application for Partial Change in Indications for Combination Therapy February 26, 2013 Press Release Mitsubishi Tanabe Pharma Corporation TENELIA® 20mg tablets, a Treatment for Type 2 Diabetes Mellitus Application for Partial Change in Indications for Combination Therapy](https://www.pdfsearch.io/img/875f771d4ce89b0834046137d3c4cdd6.jpg) | Add to Reading ListSource URL: www.mt-pharma.co.jpLanguage: English - Date: 2013-12-11 23:08:01
|
---|
54![PRECOSE® (acarbose tablets[removed]DESCRIPTION PRECOSE® (acarbose tablets) is an oral alpha-glucosidase inhibitor for use in the management of type 2 diabetes mellitus. Acarbose is an oligosaccharide which is obtained f PRECOSE® (acarbose tablets[removed]DESCRIPTION PRECOSE® (acarbose tablets) is an oral alpha-glucosidase inhibitor for use in the management of type 2 diabetes mellitus. Acarbose is an oligosaccharide which is obtained f](https://www.pdfsearch.io/img/fa89a9eff71ca872a6163c0e32c22f00.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2012-03-01 15:12:58
|
---|
55![PRECOSE® (acarbose tablets[removed]DESCRIPTION PRECOSE® (acarbose tablets) is an oral alpha-glucosidase inhibitor for use in the management of type 2 diabetes mellitus. Acarbose is an oligosaccharide which is obtained fr PRECOSE® (acarbose tablets[removed]DESCRIPTION PRECOSE® (acarbose tablets) is an oral alpha-glucosidase inhibitor for use in the management of type 2 diabetes mellitus. Acarbose is an oligosaccharide which is obtained fr](https://www.pdfsearch.io/img/23acf3a30b8c2d6c6c06a75899619d3d.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2011-03-28 12:08:24
|
---|
56![LYSOSOMAL STORAGE DISORDER Quarterly Report PROFICIENCY TESTING Volume 2, No. 2 LYSOSOMAL STORAGE DISORDER Quarterly Report PROFICIENCY TESTING Volume 2, No. 2](https://www.pdfsearch.io/img/a5521470b67f701d12f5bdd0a1aa7c61.jpg) | Add to Reading ListSource URL: www.cdc.govLanguage: English - Date: 2013-05-21 09:46:35
|
---|
57![LYSOSOMAL STORAGE DISORDER Quarterly Report PROFICIENCY TESTING August 2013 LYSOSOMAL STORAGE DISORDER Quarterly Report PROFICIENCY TESTING August 2013](https://www.pdfsearch.io/img/8d635212c74d52a6772a41a9489a3924.jpg) | Add to Reading ListSource URL: www.cdc.govLanguage: English - Date: 2013-08-26 07:08:24
|
---|
58![JANUARY[removed]UNDERSTANDING POMPE DISEASE Pompe (POM-pay) disease, also known as glycogen storage disease type II or acid maltase deficiency, is a JANUARY[removed]UNDERSTANDING POMPE DISEASE Pompe (POM-pay) disease, also known as glycogen storage disease type II or acid maltase deficiency, is a](https://www.pdfsearch.io/img/c96447383c4e81a1a5361d31e75d6058.jpg) | Add to Reading ListSource URL: www.niams.nih.govLanguage: English - Date: 2013-05-22 13:44:51
|
---|
59![Amicus Therapeutics Announces Second Quarter 2007 Financial Results Amicus Therapeutics Announces Second Quarter 2007 Financial Results](https://www.pdfsearch.io/img/99961c9948d21a723903caf087f92cdb.jpg) | Add to Reading ListSource URL: www.unitedpompe.comLanguage: English - Date: 2011-12-11 11:39:13
|
---|
60![Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease CRANBURY, N.J., June 3, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease CRANBURY, N.J., June 3, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company](https://www.pdfsearch.io/img/b19273df9b0ae70ef7639bfe3b73f669.jpg) | Add to Reading ListSource URL: www.unitedpompe.comLanguage: English - Date: 2008-06-03 09:27:22
|
---|